MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Stability Notes

No special requirements for storage.

Provenance

This compatibility recommendation is derived from all strengths of Lyrica capsules (Viatris UK Healthcare Ltd).

Stability Notes

No special requirements for storage.

Provenance

This compatibility recommendation is derived from all strengths of Lyrica capsules (Viatris UK Healthcare Ltd).

Stability Notes

No special requirements for storage.

Provenance

This compatibility recommendation is derived from all strengths of Lyrica capsules (Viatris UK Healthcare Ltd).

Stability Notes

Store in airtight containers. Protect from light and moisture. Disintegrates outside packaging.

Provenance

This compatibility recommendation is derived from Zovirax 200mg dispersible tablets (GlaxoSmithKline UK Ltd).

Stability Notes

Protect from moisture and light. Store in an airtight container.

Provenance

This compatibility recommendation is derived from Tranylcypromine 10mg tablets (Advanz Pharma).

Stability Notes

Store in airtight containers. Protect from light and moisture. Disintegrates outside packaging.

Provenance

This compatibility recommendation is derived from Zovirax 800mg dispersible tablets (GlaxoSmithKline UK Ltd).

Stability Notes

Protect from moisture.

Provenance

This compatibility recommendation is derived from Toviaz 8mg modified-release tablets (Pfizer Ltd).

Stability Notes

Protect from moisture.

Provenance

This compatibility recommendation is derived from Exforge 5mg/80mg tablets (Novartis Pharmaceuticals UK Ltd).

Stability Notes

Protect from moisture.

Provenance

This compatibility recommendation is derived from Exforge 5mg/160mg tablets (Novartis Pharmaceuticals UK Ltd).

Stability Notes

Protect from moisture.

Provenance

This compatibility recommendation is derived from Exforge 10mg/160mg tablets (Novartis Pharmaceuticals UK Ltd).

Print this list

Medicines under this category are suitable for use inside MCAs, although this is likely to be an off-label use.
Medicines under this category can theoretically be used inside an MCA; however, mitigations may need to be considered.
Medicines under this category are not suitable for use inside MCAs.
We do not have stability information for these medicines and therefore cannot make a recommendation on suitability in an MCA.